

Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability

NCT05744479

Status	RECRUITING
Phase	Phase 4
Sponsor	Centre for Addiction and Mental Health
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (11)

- Stable outpatients
- Age 16-65 years
- Diagnosed with an IDD
- On maintenance treatment with an antipsychotic (stable dose for e3 months).
- BMI must be e30 kg/m2, OR e27 kg/m2 with at least one weight-related comorbidity (treated or untreated) such as: hypertension, dyslipidaemia, obstructive sleep apnea, or impaired fasting glucose, OR ≥ 25 for individuals who have gained $\geq 5\%$ body weight in association with AP use.

... and 6 more (see full listing online)

Exclusion (10)

- Females who are nursing, currently pregnant, or have a positive pregnancy test
- Clinical or laboratory evidence of uncompensated cardiovascular, endocrine, haematological, hepatic, renal, or pulmonary disease
- Previous treatment and lack of efficacy or tolerability with metformin
- History or diagnosis of Type 1 Diabetes (T1D) or Type 2 Diabetes (TD2) or fasting blood work, HbA1c $\geq 6.5\%$
- History of metabolic acidosis or lactic acidosis

... and 5 more (see full listing online)

Locations (1 total)

Centre for Addiction and Mental Health, Toronto, Ontario, Canada